| Name | CYP3A4 |
|---|---|
| Synonyms | CP33; CYP3; HLP; CYP3A; CP34; CYP 3A4; CYP 3; CYP3A3… |
| Name | sulfuric acid |
|---|---|
| CAS | sulfuric acid |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 15229170 | Karanam BV, Welch CJ, Reddy VG, Chilenski J, Biba M, Vincent S: Species differential stereoselective oxidation of a methylsulfide metabolite of MK-0767 [(+/-)-5-[(2,4-dioxothiazolidin-5-yl) methyl]-2-methoxy-N-[[(4-trifluoromet hyl) phenyl] methyl] benzamide], a peroxisome proliferator-activated receptor dual agonist. Drug Metab Dispos. 2004 Oct;32(10):1061-8. Epub 2004 Jun 30. M25 is a metabolite generated from MK-0767 following CYP3A4-mediated TZD ring opening and subsequent methylation of the sulfide intermediate M22. |
3(0,0,0,3) | Details |
| 17253885 | Zhang H, Cui D, Wang B, Han YH, Balimane P, Yang Z, Sinz M, Rodrigues AD: Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug. Clin Pharmacokinet. 2007;46(2):133-57. Cytochrome P450 (CYP) 3A4-mediated EE 2-hydroxylation is the major pathway of oxidative metabolism of EE. |
3(0,0,0,3) | Details |
| 17315539 | Wu WN, McKown LA, Reitz AB: Metabolism of the new anxiolytic agent, a pyrido [1,2-] benzimidazole (PBI) analog (RWJ-53050), in rat and human hepatic S9 fractions, and in dog; identification of cytochrome p450 isoforms mediated in the human microsomal metabolism. Eur J Drug Metab Pharmacokinet. 2006 Oct-Dec;31(4):277-83. The in vitro and in vivo metabolism of RWJ-53050, an anxiolytic agent, was investigated after incubation with rat and human hepatic S9 fractions, and human microsomes and 7 microsomes containing individual human CYP isoforms, CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4 in the presence of -generating system, and a single oral dose administration to dogs (30 mg/kg). |
2(0,0,0,2) | Details |
| 17220239 | Vincent SH, Reed JR, Bergman AJ, Elmore CS, Zhu B, Xu S, Ebel D, Larson P, Zeng W, Chen L, Dilzer S, Lasseter K, Gottesdiener K, Wagner JA, Herman GA: Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C] sitagliptin in humans. Drug Metab Dispos. 2007 Apr;35(4):533-8. Epub 2007 Jan 12. CYP3A4 was the major cytochrome P450 isozyme responsible for the limited oxidative metabolism of sitagliptin, with some minor contribution from CYP2C8. |
1(0,0,0,1) | Details |
| 16718649 | Baldacci A, Thormann W: Capillary electrophoresis contributions to the hydromorphone metabolism in man. Electrophoresis. 2006 Jun;27(12):2444-57. Using the same CE conditions as previously developed for the analysis of urinary and its metabolites, HMOR and its phase I metabolites produced by N-demethylation, 6-keto-reduction and N-oxidation and phase II conjugates of HMOR and its metabolites formed with and sulfuric acid could be detected in urine samples of a patient that were collected during a pharmacotherapy episode with daily ingestion of 48 mg of HMOR The CE-MS (n) data obtained with the HMOR standard, synthesized hydromorphol and hydromorphone-N-oxide, and CYP3A4 in vitro produced norhydromorphone were employed to identify the metabolites. |
1(0,0,0,1) | Details |
| 16035375 | Fuhr U, Kober S, Zaigler M, Mutschler E, Spahn-Langguth H: Rate-limiting biotransformation of is mediated by CYP1A2. . Int J Clin Pharmacol Ther. 2005 Jul;43(7):327-34. Mean inhibitor induced changes of 4'--TA formation were as follows: Furafylline 25 microM (CYP1A2), complete inhibition (-100%); 250 microM (CYP1A2 inhibitor/CYP2C 19 substrate), -30%; 25 microM (CYP2A6), -11%; quinidine 25 microM (CYP2D6), -9%; ketoconazole 25 microM (CYP3A), -18%; and erythromycin 250 microM (CYP3A), -8%. |
1(0,0,0,1) | Details |